TNK (Tenecteplase) for Acute STEMI
Pre-hospital TNKase is a real opportunity to offer timely reperfusion to as many patients as possible in an easy way, an opportunity that the health care system cannot miss - Giovanni Melandri
HWN Suggests
Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction
There are indeed several reasons for choosing TNKase: the easy way it may be used in ambulance (this use is also a Class IA ACCP recommendation), the high thrombolytic potency with a decreased risk of inducing major bleeds, and the really competitive results that may be expected for that majority of patients presenting in the first 3 hours, compared with P-PCI.
Indeed, TNKase is now embraced in many pre-hospital thrombolytic reperfusion protocols, such as the Vienna STEMI Registry, The Mayo Clinic STEMI Protocol, and The French FAST-MI registry. Therefore, a modern, TNKase-based “fibrinolytic strategy” is now offered to the health care system, which may overcome the huge logistic…
Articles of Interest
Guard Your Heart
The ease of administration of tenecteplase may facilitate more RAPID TREATMENT in and out of hospital.
Safety and Efficacy of Third Generation Thrombolytic- Tenecteplase in Acute Myocardial Infarction
Tenecteplase is the safest drug in our setup with the least rate of complications. The efficacy of the drug is still maintained even if it is given after a 6-hours’ time window. This makes Tenecteplase a choice for pre-hospital thrombolysis. The higher patency rates and least rates of re-infarction are due to the efficacy of the drug in achieving successful thrombolysis and continuous infusion of heparin till taken up for angiography. The mortality rate is higher in females compared to males. About one-fourth of the patients had the insignificant disease after thrombolysis.
Tenecteplase (TNKase™): A Clinical Review
Tenecteplase, a fibrin specific thrombolytic with a sufficiently long half-life to enable single bolus administration, has proven to be as efficacious as t-PA in reducing mortality rates in patients presenting with AMIs.
Tenecteplase: Single-Bolus Thrombolytic Therapy for Acute Myocardial Infarction
Tenecteplase is a bioengineered variant of alteplase, a commonly used second generation thrombolytic agent. The "TNK" of TNKaseTM refers to sites of amino acid modification. These modifications result in increased fibrin specificity, reduced plasma clearance and improved resistance to inactivation.
Thrombolytic Use for STEMI: What ED Clinicians Should Know
Tenecteplase has the shortest administration time and is the most fibrin-specific of the three fibrin-specific agents. It is administered as one IV bolus over 5 seconds and the selected dose is weight-dependent. For patients 75 years or older, a reduced dose of tenecteplase should be considered.
What is the Difference Between tPA and TNK
The main difference between tPA and TNK is that tPA, or tissue plasminogen activator, is one of the essential components of the dissolution of blood clots, whereas TNK is a genetically modified form of tissue plasminogen activator.
Resources
THKase
The only lytic delivered as a 5-second IV bolus for the treatment of acute ST elevation myocardial infarction (STEMI), TNKase® (tenecteplase) enables you to intervene quickly.
Life in the Fastlane
Reperfusion arrhythmias (in myocardial infarction) – 10%.
StatPearls
The most widely used indications are acute myocardial infarction and acute ischemic stroke.
